Aspargo’s oral spray suspension formulation of sildenafil citrate (Sildenafil Oral Spray), the active ingredient in VIAGRA^®, is a novel and convenient route of administration for this commonly prescribed medication for erectile dysfunction. Aspargo’s unique oral spray formulation is designed to offer patients an alternative to tablet medications, such as VIAGRA^® and Cialis^® and their respective generic equivalents.

Aspargo Labs owns the exclusive commercialization rights to Sildenafil Oral Spray in the United States and more than 30 countries throughout Europe, Russia, Asia, the Middle East, South America, the United Kingdom and Canada under a licensing agreement with Farmalíder S.A. (Madrid, Spain), a leader in the Spanish OTC and ibuprofen market.

Market Exclusivity & IP Protection

Aspargo is seeking to obtain FDA authorization to market Sildenafil Oral Spray in the United States pursuant to the approval pathway described in section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This regulation provides that new routes of administration for a previously approved drug qualify for an expedited form of approval.

Aspargo is seeking to obtain regulatory authorization to market Sildenafil Oral Spray in Germany and various European countries under the “decentralized procedure”, whereby a marketing authorization granted in one “Member State” (the “Reference Member State”) can be recognized simultaneously in other EU countries (the “Concerned Member States”).

LEARN MORE

Dosage

Sildenafil Oral Spray is dispensed from a metered dose pump that delivers exactly 12.5 mg per push of the pump. Patients will administer a physician prescribed number of metered sprays into the mouth when needed prior to sexual activity. Two sprays are equivalent to a 25 mg VIAGRA^® tablet; four sprays are equivalent to a 50 mg VIAGRA^® tablet and eight sprays are equivalent to a 100 mg VIAGRA^® tablet.